Palmitoyl tetrapeptide-7

At a glance

Overview

The ingredient consists of the four-residue sequence glycine-glutamine-proline-arginine linked to a palmitoyl group. It is chemically distinct from its frequent companion palmitoyl tripeptide-1. Pairing them in a commercial complex may be useful for formulation, but it creates an evidence-attribution problem: an improved finished product does not reveal the contribution of each peptide. The two molecules retain different chemical identities even when formulated together, so their shared blend context cannot establish identical biological activity or independent efficacy. Marketing language about matrix repair or age reversal should be interpreted as a claim requiring specific outcome data, rather than a consequence automatically proven by the ingredient’s structure.

Supporting sources [1] [2] [3] [4]

How it works

The peptide is marketed within a matrikine-style signaling concept, with proposed effects on inflammatory or matrix-related cellular responses. Its GQPR sequence is described in the CIR assessment as related to an immunoglobulin fragment. That structural relationship is not proof of a clinically useful anti-inflammatory action. Human evidence needs to distinguish the isolated peptide from companion actives and from the moisturizing properties of the formulation.

Supporting sources [1] [2] [3] [4]

The finished-product evidence

A 2024 study examined an eye cream combining these two palmitoylated peptides with a fermentation filtrate and N-acetylneuraminic acid. It included fibroblast experiments and a twelve-week human evaluation. The results concern that complete intervention. They cannot demonstrate that palmitoyl tetrapeptide-7 alone produced changes in hydration, elasticity, or collagen-related measurements.

Supporting sources [1]

What Matrixyl 3000 documentation establishes

Croda’s documentation confirms that Matrixyl 3000 contains both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. It also reports supplier efficacy claims. The composition is useful factual information, while the claims require appraisal of the underlying design and replication. The ingredient blend is not a single peptide with two interchangeable names.

Supporting sources [2]

Keep topical assessment separate from approval

The CIR assessment covers described cosmetic uses of this ingredient family. It does not demonstrate an injected therapeutic effect. Cosmetic status is not FDA drug approval. Product tolerability and the strength of the specific appearance claim still need to be assessed for the finished formulation.

Supporting sources [3] [4]